Elias Chalhub
Neurology · Mobile, ALNPI 1922043421
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $572 and has fallen 62.8% since, to $213 in 2025. That places this record below the midpoint for neurology clinicians in AL, where the typical reported total is $2,219.
Across 135 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$268
- AbbVie$233
- Supernus Pharmaceuticals, Inc.$189
- SK Life Science, Inc.$176
- UCB, Inc.$176
- EMD Serono, Inc.$106
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,337100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 22 | $268 |
| AbbVie(2 entities) | 12 | $233 |
| Supernus Pharmaceuticals, Inc. | 14 | $189 |
| SK Life Science, Inc. | 6 | $176 |
| UCB, Inc. | 8 | $176 |
| EMD Serono, Inc. | 8 | $106 |
| Azurity Pharmaceuticals, Inc. | 4 | $99 |
| Acadia Pharmaceuticals Inc | 5 | $95 |
| Biogen | 5 | $86 |
| Argenx US, Inc. | 3 | $84 |
| Genentech USA, Inc. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 5 | $80 |
| AstraZeneca(2 entities) | 3 | $60 |
| Eisai Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Neurelis, Inc. | 2 | $35 |
| Portola Pharmaceuticals, LLC | 2 | $32 |
| Baxter Healthcare | 2 | $31 |
| Lilly USA, LLC | 2 | $30 |
| Springworks Therapeutics, Inc. | 1 | $29 |
| Pfizer | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| Tanabe Pharma America, Inc. | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Sanofi | 1 | $18 |
| Amgen | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Merz North America, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Zogenix Inc. | 1 | $11 |
| Aucta Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$2,337 in reported general payments places this provider in the 50th percentile of 255 neurology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbamazepine ErCarbamazepine | 19 | $4,499 |
| Phenobarbital | 18 | $1,135 |
| Divalproex Sodium ErDivalproex Sodium | 23 | $1,122 |
| Levetiracetam | 40 | $857 |
| Phenytoin Sodium Extended | 13 | $730 |
| Risperidone | 17 | $414 |
| Oxcarbazepine | 16 | $377 |
| Phenytoin | 13 | $328 |
| Baclofen | 15 | $220 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 14 | $154 |
| Gabapentin | 13 | $142 |
Paid to pharmacies, not to this prescriber.
Other neurology in Mobile
- Daniel DeesMobile$799K
- Hayden LongMobile$386K
- Charles MarkleMobile$212K
- William KilgoMobile$200K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$160K
- Steve CordinaMobile$69K
- Thomas FosterMobile$51K
- Laura MintoMobile$33K
- Andrew ManleyMobile$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.